This article is mentioned in:

Introduction

Hepatic fibrosis is the final consequence of many chronic liver injuries that later develop in cirrhosis and hepatocellular carcinoma (HCC), which are leading causes of morbidity and mortality worldwide (1). Regardless of the cause, hepatic fibrosis is always characterized by the abnormal accumulation of extracellular matrix (ECM). Accumulating evidence has showed that in liver injury, hepatic stellate cells (HSCs) undergo a phenotypic transformation from quiescent, non-proliferating, retinoid-storing cells to a proliferating, matrix-producing phenotype similar to myofibroblasts (MFBs) (2–4). Thus, the factors that regulate the activation, proliferation and functions of HSCs represent important antifibrotic targets (5). Clinical reports suggest that advanced hepatic fibrosis is potentially reversible (6); however, therapeutic options are limited. Therefore, there is an urgent need for novel effective agents capable of inhibiting the function of HSCs.

The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play essential roles in the signaling of numerous cytokines that have been implicated in the pathogenesis of many diseases. The family of JAKs comprises four members in mammals: JAK1, JAK2, JAK3 and tyrosine kinase 2 (Tyk2) (7). After the engagement of cytokine receptors constitutively bound to JAK, JAK is activated by a conformational change and phosphorylated. This in turn phosphorylates the cytokine receptors, resulting in the phosphorylation of signal transducer and activator of transcription (STAT) that subsequently translocates into the nucleus, in order to regulate gene expression (8). The JAK/STAT pathway mediates a plethora of cellular functions including defense against pathogens, differentiation, proliferation, apoptosis, metabolism and cellular transformation (7,9). Some JAK1/2 inhibitors have been demonstrated to exert protective effects in fibrotic diseases, such as bone marrow fibrosis and myelofibrosis (10). However, the therapeutic effect of JAK inhibition in hepatic fibrosis has not been investigated to date, to the best of our knowledge. The JAK inhibitor SHR0302 (C18H22N8O2S·H2SO4, MW, 512), binds to JAK1 with a stronger affinity than to other JAKs (selectivity for JAK1 is >10 times for JAK2, 77 times for JAK3 and 420 times for Tyk2). This study examined the effects of the JAK inhibitor SHR0302 on the activation, proliferation, migration, collagen production and apoptosis of HSCs and the underlying mechanisms responsible for these effects. Our findings demonstrated the protective effects of SHR0302 on hepatic fibrosis by inhibiting HSC functions.

Materials and methods

Chemicals and reagents

SHR0302 was obtained from Jiangsu Hengrui Medicine Co., Ltd. (Jiangsu, China). MTT was purchased from Sigma Chemical Co. (St. Louis, MO, USA). The cell apoptosis Annexin V/PI detection kit was obtained from Shanghai Bestbio (Shanghai, China). Transforming growth factor β1 (TGF-β1) was obtained from Peprotech EC, Ltd. (London, UK). Phosphorylated (p-)STAT3 (9145), STAT3 (4904), p-Akt (4058) and Akt (4691) primary antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA). p-JAK1, JAK, cleaved caspase-3 (sc-98785), α-smooth muscle actin (α-SMA; sc-53015), collagen I (sc-59772) and collagen III (sc-8780-R) primary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Bcl-2 (TA803003), Bax (TA346891) and β-actin (TA-09) primary antibodies were purchased from ZSGB-Bio (Beijing, China). Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were obtained from Gibco (Carlsbad, CA, USA). Other chemicals used in the experiment were of analytical grade and obtained from commercial sources.

Cell culture

The HSC-T6 cell line was obtained from the Institute of Liver Disease at the Shanghai University of Traditional Chinese Medicine (Shanghai, China). The HSCs were cultured at 37°C in an atmosphere of 5% CO2 in DMEM containing 10% FBS, 2 mmol/l L-glutamine, 100 U/ml of penicillin and 100 µg/ml of streptomycin.

Cell proliferation assay

The MTT assay was used to evaluate the proliferation of HSCs. Briefly, the HSCs were plated at a density of 5×104 cells/ml in 96-well culture plates. The confluent cells were growth-arrested in DMEM containing 0.5% FBS for 24 h. Subsequently, the cells were incubated with SHR0302 at various concentrations (10−9, 10−8, 10−7, 10−6 and 10−5 mol/l) for 48 h. Following treatment, MTT solution (5.0 mg/ml in PBS) was added (20.0 µl/well), and the plates were incubated at 37°C in 5% CO2 for a further 4 h. The MTT-formazan product was dissolved in 150 µl dimethyl sulfoxide (DMSO)/well. After 10 min, the plates were read on a BioTek Elx808 microplate reader (Winooski, VT, USA) at 570 nm.

Migration assay

To examine the effects of SHR0302 on the migration of HSCs, a wound-healing assay was performed. The HSCs were seeded in 6-well plates at 80–90% confluency. The cell monolayer was then wounded with a 200 µl-pipette. After washing with PBS three times to remove cell debris, the cells were incubated with 5 ng/ml TGF-β1 and SHR0302 at various concentrations (10−9, 10−8, 10−7, 10−6 and 10−5 mol/l) for 24 h, and then images were captured under a microscope (IX71; Olympus, Tokyo, Japan) at 0 and 24 h after treatment. Cell migration was determined by measuring the movement of cells into the scraped area and quantitative analysis showing the percentage wound closure relative to different conditioned media from the HSCs was performed using Adobe Photoshop Elements 6.0 software.

Flow cytometric analysis

The HSCs were plated in 6-well plates and treated with SHR0302 (10−9, 10−8, 10−7, 10−6 and 10−5 mol/l) for 48 h. After being harvested by trypsinization, the cells were washed twice with cold PBS, and 400 µl 1X binding buffer was added to each sample tube at a density of 1.0×l06 cells/ml. The sample solutions were then transferred to a 5 ml culture tube and incubated with 5 µl FITC-conjugated Annexin V for 15 min at 2–8°C in the dark, and 10 µl PI for 5 min at 2–8°C in the dark. The cells were collected and apoptosis was examined using a flow cytometer (FC 500; Beckman Coulter, Inc., Brea, CA, USA).

Western blot analysis

Proteins were then extracted from the cells in RIPA lysis buffer [50 mmol/l Tris-HCl, pH 7.4, 150 mmol/l NaCl, 10 mmol/l phenylmethylsulfonyl fluoride (PMSF), 1 mmol/l ethylenediaminetetraacetic acid (EDTA), 0.1% sodium dodecyl sulfate (SDS), 1% Triton X-100, 1% sodium deoxycholate]. The protein concentration was determined using the Bradford assay. A protein sample was mixed with the 5X sample buffer (4:1) (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and heated in boiling water for 10 min. The proteins were resolved by SDS-PAGE, transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore, Bedford, MA, USA). After blocking with 5% non-fat milk (blocking solution) at room temperature, the membrane was incubated with α-SMA, collagen I, collagen III, cleaved caspase-3, Bcl-2, Bax, p-JAK1, JAK1, p-STAT3, STAT3, p-Akt, Akt and β-actin primary antibodies (1:1,000) overnight at 4°C. After washing the blot in TBST three times, horseradish peroxidase (HRP)-conjugated secondary antibodies were applied for 2 h at room temperature. After extensive washing in TBST, immunodetection was visualized by enhanced chemiluminescence (Pierce, Rockford, IL, USA) using hydrogen peroxide and luminol as substrates. Autoradiographs were scanned using ImageQuant LAS 4000 mini (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). The density of the specific bands was quantified using ImageJ software (National Institutes of Health, Bethesda, MD, USA).

Statistical analysis

Data are expressed as the means ± SD and statistical analysis was performed using one-way ANOVA. All statistical analysis was performed with the statistical package SPSS 13.0 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

SHR0302 suppresses the activation of HSCs

Since α-SMA is an marker of activated HSCs (11), we investigated the activity of HSCs by examining the expression of α-SMA. As illustrated in Fig. 1, SHR0302 at various concentrations markedly inhibited the expression of α-SMA compared with the untreated group. These results suggest that SHR0302 inhibits the activation of HSCs by suppressing the expression of α-SMA.

Figure 1 Effect of SHR0302 on the expression of α-smooth muscle actin (α-SMA) in hepatic stellate cells (HSCs). (A) Western blots of α-SMA expression in HSCs cultured with SHR0302 at the various concentrations (10−9, 10−8, 10−7, 10−6 and 10−5 mol/l) for 24 h. HSCs without SHR0302 treatment were used as the control. (B) The semi-quantitative analysis of α-SMA expression in the conditioned media from HSCs. The data are expressed as the means ± SD in the three independent experiments. The band intensity of α-SMA was quantified by densitometry and normalized to β-actin. *P<0.05, **P<0.01 compared with the control group.

SHR0302 inhibits the proliferation of HSCs

The effect of SHR0302 on the proliferation of HSCs was detected using the MTT assay. HSCs were incubated with SHR0302 at various concentrations (10−9, 10−8, 10−7, 10−6 and 10−5 mol/l). As shown in Table I, the inhibitory rates of SHR0302 (10−9, 10−8, 10−7, 10−6 and 10−5 mol/l) in HSCs were 6.376, 6.650, 14.551, 19.143 and 48.640%, respectively, following treatment for 48 h. The MTT experiment confirmed that HSCs were sensitive to SHR0302, that SHR0302 displayed an inhibitory effect on the proliferation of HSCs, and that inhibition ocurred in a concentration-dependent manner.

Table I Effect of SHR0302 on the proliferation of HSCs (means ± SD, n=8).

Table I

Effect of SHR0302 on the proliferation of HSCs (means ± SD, n=8).

Group	Concentration (mol/l)	48 h
		A570nm	Inhibitory rate (%)
Control	–	0.782±0.060	–
SHR0302	10−9	0.733±0.055	6.376
	10−8	0.730±0.056	6.650
	10−7	0.669±0.080a	14.551
	10−6	0.632±0.025a	19.143
	10−5	0.402±0.046a	48.640

a P<0.01 compared with control group. HSC, hepatic stellate cell.

SHR0302 inhibits the migration of HSCs

To determine the effect of SHR0302 on the migration of HSCs, wound-healing assays was performed after exposing cells to different concentrations of SHR0302 in the presence or absence of TGF-β1. As shown in Fig. 2, TGF-β1 markedly enhanced cell migration during the wound-healing process compared with the control group. By contrast, SHR0302 effectively attenuated the migration ability of HSCs at concentrations of 10−7, 10−6 and 10−5 mol/l, which shows that SHR0302 directly inhibited the migration of HSCs.

Figure 2 Effect of SHR0302 on the migration of hepatic stellate cells (HSCs). (A) Images of HSCs following treatment with SHR0302 at concentrations of 10−9, 10−8, 10−7, 10−6 and 10−5 mol/l at 0 and 24 h in TGF-β1-stimulated HSCs. HSCs without TGF-β1 treatment were used as the control group. (B) Quantitative analysis showed the percentage wound closure relative to different conditioned media from HSCs using Adobe Photoshop Elements 6.0 software. The data are expressed as the means ± SD in the three independent experiments. ##P< 0.01 compared with the control group, *P<0.05, **P<0.01 compared with the TGF-β1 group.

SHR0302 decreases the expression of collagen I and collagen III in HSCs

To determine the effect of JAK inhibitor SHR0302 on collagen I and collagen III synthesis in HSCs, western blot analysis was performed. TGF-β1 strongly promotes HSCs to synthesize ECM, such as collagen and fibronetin (12,13). The control groups showed low levels of collagen I and collagen III whereas treatment with TGF-β1 significantly increased the expression of collagen I and collagen III in HSCs. SHR0302 treatment at concentrations of 10−8, 10−7, 10−6 and 10−5 mol/l markedly reduced the production of both collagen I and collagen III in HSCs (Fig. 3). Our data therefore demonstrated that SHR0302 reduces collagen deposition.

Figure 3 Effects of SHR0302 on collagen I and collagen III expression in hepatic stellate cells (HSCs). (A) Western blots of collagen I and collagen III expression in TGF-β1-stimulated HSCs treated with various concentrations of SHR0302 (10−9, 10−8, 10−7, 10−6 and 10−5 mol/l). (B) The semi-quantitative analysis of collagen I and collagen III expression in the conditioned media from HSCs. The data are expressed as the means ± SD from three independent experiments. The band intensity of collagen I and collagen III were quantified by densitometry and normalized to β-actin. #P< 0.05, ##P< 0.01 compared with the control group, *P<0.05, **P<0.01 compared with the TGF-β1 group.

SHR0302 induces the apoptosis of HSCs

To determine whether SHR0302 induced the apoptosis of HSCs, the apoptosis rates were detected by Annexin V/PI staining. As shown in Fig. 4, the percentage of apoptotic cells increased from 6.76% in the control group to 75.45% in the SHR0302 10−5 mol/l treatment group of HSCs after 48 h. These results showed that SHR0302 significantly induced the apoptosis of HSCs.

Figure 4 Effect of SHR0302 on the apoptosis of hepatic stellate cells (HSCs). (A) The representative flow cytometry dot plot of each group. HSCs without any SHR0302 treatment were used as the control group. Frames are divided into four quadrants: early apoptotic cells (Annexin V+/PI−) are in quadrant III; late apoptotic cells (Annexin V+/PI+) are in quadrant II; normal cells (Annexin V−/PI−) are in quadrant IV; and necrotic cells injured by experimental manipulation (Annexin V−/PI+) are in quadrant I. (B) Percentages of apoptotic cells (early apoptotic cells and late apoptotic cells) in HSCs treated with SHR0302. The data are expressed as the means ± SD from three independent experiments. *P<0.05, **P<0.01 compared with the control group.

SHR0302 modulates the expression of Bcl-2 and Bax in HSCs

To identify a possible mechanism by which SHR0302 induced the apoptosis of HSCs, western blot analysis was performed (Fig. 5A). The results of western blot analysis revealed the decreased expression of Bcl-2 in the SHR0302-treated HSCs compared with the control group. SHR0302 at various concentrations markedly inhibited Bcl-2 expression. However, the expression of Bax was elevated at various concentrations of SHR0302-treated cells compared with the control group. As shown in Fig. 5B, the Bax to Bcl-2 ratio was significantly increased in the SHR0302-treated cells compared with the control group. The results indicated that SHR0302 induced the apoptosis of HSCs mainly by regulating the expression of Bcl-2 family proteins.

Figure 5 Effects of SHR0302 on Bcl-2 and Bax protein expression in hepatic stellate cells (HSCs). (A) Bcl-2 and Bax protein expression in the control group and the groups treated with various concentrations of SHR0302 (10−9, 10−8, 10−7, 10−6 and 10−5 mol/l). (B) The semi-quantitative analysis of Bax/Bcl-2 ratio in the conditioned media from HSCs. The data are expressed as the means ± SD from three independent experiments. The band intensity of Bcl-2 and Bax were quantified by the ratio of Bax to Bcl-2. *P<0.05, **P<0.01 compared with the control group.

SHR0302 increases caspase-3 activation in HSCs

To determine whether SHR0302 affects the activation of caspase-3 in HSCs, the activation of caspase-3 was quantified through western blot analysis. As shown in Fig. 6, a low level of cleaved caspase-3 was observed in the control group. Treatment with various concentrations of SHR0302 markedly increased the levels of cleaved caspase-3 in HSCs.

Figure 6 Effect of cleaved caspase-3 protein expression in hepatic stellate cells (HSCs). (A) Treatment of HSCs with SHR0302 (10−9, 10−8, 10−7, 10−6 and 10−5mol/l) increased the expression of cleaved caspase-3. (B) The semi-quantitative analysis of cleaved caspase-3 in the conditioned media from HSCs. The data are expressed as the means ± SD from three independent experiments. The band intensity of cleaved caspase-3 was quantified by densitometry and normalized to β-actin. *P<0.05, **P<0.01 compared with the control group.

SHR0302 suppresses the JAK1/STAT 3 signaling pathway in HSCs

The pathogenesis of hepatic fibrosis is closely associated with the activation of STAT3 (14). SHR0302 resulted in dose-dependent decreases in JAK1 and STAT3 phosphorylation (Fig. 7). Also, similar concentrations of SHR0302 exerted effects on the activation, proliferation, collagen deposition and apoptosis of HSCs. These findings suggest that the mechanism responsible for the effects of SHR0302 on HSC function occurs through the inhibition of JAK1/STAT3 signaling pathways.

Figure 7 Effects of SHR0302 on Janus kinase (JAK)-1 and signal transducer and activator of transcription (STAT)-3 activation in HSCs. Western blots showed that SHR0302 causes the inhibition of (A) JAK1 and (C) STAT3 activation in HSCs. (B and D) The changes in phosphorylated (p-)JAK1 and p-STAT3 are expressed as ratios of phosphorylated/unphosphorylated forms and are shown as a bar diagram. The data are expressed as the means ± SD from three independent experiments. Densitometry values in the histograms were expressed as fold change relative to the control, which was assigned a value of 1. *P<0.05, **P<0.01 compared with the control group.

SHR0302 suppresses the Akt signaling pathway in HSCs

The Akt signaling pathway is a major regulator of crucial cell functions such as cell growth, survival and proliferation. The inhibition of Akt activation may induce the apoptosis of HSCs and suppress collagen synthesis (15,16) in hepatic fibrosis. Thus, we examined whether SHR0302 has an effect on the Akt signaling pathway. The results (Fig. 8) showed that SHR0302 significantly suppressed the Akt signaling pathway at concentrations of 10−5, 10−6 and 10−7 mol/l.

Figure 8 Effects of SHR0302 on Akt activation in hepatic stellate cells (HSCs). (A) Treatment with SHR0302 (10−9, 10−8, 10−7, 10−6 and 10−5 mol/l) in HSCs inhibited the expression of phosphorylated (p-)Akt. (B) The changes in p-Akt are expressed as the ratio of phosphorylated/unphosphorylated forms and are shown as a bar diagram. The data are expressed as the means ± SD from three independent experiments. Densitometry values in the histograms are expressed as the fold change relative to the control, which was assigned a value of 1. *P<0.05, **P<0.01 compared with the control group.

Discussion

Hepatic fibrosis is the pathological consequence of chronic liver diseases, resulting from the progressive accumulation of ECM, which is mainly enriched in types I and III fibrillar collagens. In the advanced stages, fibrosis leads to cirrhosis, a condition characterized by abnormal liver architecture, failing liver function and portal hypertension as well as a high susceptibility to infection and to developing HCC (17,18). To date, the most effective therapy for the treatment of hepatic fibrosis involves removal of the causative agent. During liver injury, HSCs undergo transdifferentiation from the lipocyte phenotype to MFBs; during this process, lipid droplets decrease in size and number whereas proliferation, migration rate and ECM production are increased (19,20), and this appears to be the dominant driving force in fibrosis. These studies explored the rationale for choosing HSCs as a target for pharmacological, molecular and other novel therapeutics, for potential application in the treatment of hepatic fibrosis. Our data demonstrated that the abrogation of the JAK1/STAT3 signaling pathway, induced by JAK inhibitor SHR0302 in HSCs, SHR0302 (10−9–10−5 mol/l) exerted an inhibitory effect on the activation, proliferation and migration of HSCs. Additionally, the expression of collagen I and collagen III was decreased after treatment with SHR0302. Furthermore, SHR0302 induced the apoptosis of HSCs, which may occur through the regulation of caspase-3 and the Bcl-2 family.

Once HSCs are activated, they become α-SMA-expressing MFBs and migrate to the site of hepatic injury. Once there, they proliferate and express various signal transduction proteins, producing both pro-inflammatory cytokines and a great deal of collagen-rich ECM (21,22). In fact, the majority of antifibrotic treatments currently under evaluation are aimed at inhibiting the activation and proliferation of HSCs as well as ECM synthesis (23). For this reason, in hepatic fibrosis, α-SMA is considered as an indicator of activated HSCs, and contributes to the proliferation and migration of HSCs as well as collagen deposition. In previous studies, the activation of renal interstitial fibroblasts was accompanied by the phosphorylation of STAT3; the inhibition of the STAT3 pathway inhibited the expression of α-SMA and fibronectin in a dose- and time-dependent manner (24), and suppressed collagen expression in renal fibrosis (25). Furthermore, a JAK inhibitor through STAT3 signaling reduced the leptin-mediated increase in the levels of α-SMA and the activity of HSCs in hepatic fibrosis (26). The MTT assay in our study demonstrated that the JAK inhibitor SHR0302 significantly decreased the proliferation of HSCs. Furthermore, western blot analysis demonstrated that following treatment with SHR0302, the expression of α-SMA was decreased in HSCs which suggests that the activation of HSCs was suppressed.

Cell migration is a vital step in the development and aggravation of several diseases, from organ fibrosis to cancer (27). The inhibition of interleukin (IL)-6-induced JAK/STAT3 phosphorylation strongly reduced the proliferation and migration of glioblastoma cells (28), and the inhibition of STAT3 expression delayed cell migration in keloid fibroblasts (29). The migration of HSCs may contribute to their accumulation at sites of liver injury. Following activation, cultured HSCs migrate in response to many stimuli. In the present study, wound-healing assays were designed to determine the migratory ability of HSCs following treatment with SHR0302. The results showed that SHR0302 significantly inhibited the migration of HSCs and provided new insights into the potential use of SHR0302 for controlling the development of hepatic fibrosis.

The most striking biological consequence of the activation of HSCs is the marked increase in collagen deposition. In the human body, collagen represents about one third of the total protein, but only 5 to 10% of the protein in a normal liver. In cirrhosis, however, it amounts to 50% or more (30). The principal ECM protein products in the progression of liver fibrogenesis are predominantly collagen types I and III (31,32). The blockade of STAT3 signaling inhibits collagen I in hepatic fibrosis (26,33). During the development of fibrosis, HSCs respond to TGF-β by moving to a MFB phenotype, which in turn produces a higher deposition of ECM proteins including collagen I and collagen III (13,34). The results of western blot analysis revealed that TGF-β1 induced the activation of HSCs which expressed high levels of collagen I and collagen III. Following treatment with SHR0302, type I and III collagen expression was suppressed, suggesting that SHR0302 inhibits the expression of collagen, and further decreased the deposition of ECM.

Apoptosis is a physiological process of programmed cell death that plays a vital role in maintaining tissue homeostasis (35). The apoptosis of activated HSCs is a key factor in the regression of liver fibrosis; emerging experimental and clinical evidence indicates that even cirrhosis is potentially reversible (5,6). The key to this is the discovery that reversion of fibrosis is accompanied by the clearance of HSCs by apoptosis. Furthermore, proof-of-concept studies in rodents have demonstrated that the experimental augmentation of the apoptosis of HSCs promotes the regression of fibrosis (36,37). Our flow cytometry assays revealed that SHR0302 significantly induces the apoptosis of HSCs. To further elucidate the possible pro-apoptotic mechanisms induced by SHR0302, the expression of the Bcl-2 family proteins and caspase-3, which are acknowledged apoptosis-related regulators, was examined. Activated HSCs are resistant to many pro-apoptotic stimuli, and the main survival signal is the overexpression of Bcl-2 family members (38,39). The previous study showed evidence that freshly isolated HSCs possessed high levels of the pro-apoptotic molecule Bax and undetectable expression of Bcl-2, a potent inhibitor of apoptotic cell death (39). Activated HSCs/MFBs had a complete reversal in the Bcl-2/Bax ratio, and Bcl-2-silenced cells were susceptible to apoptosis. The inhibition of STAT3 is associated with decreased Bcl-2 expression and increased Bax expression in many diseases (40–42). And in our study, western blot analysis revealed the decreased expression of Bcl-2 and elevated levels of Bax in the HSCs treated with SHR0302 compared with the control group. These results suggest that SHR0302 modulates the expression of Bcl-2 family proteins. Caspases are known for playing an important role in the execution of apoptosis, which frequently activates death proteases, catalyzing the specific cleavage of many pivotal cellular proteins (43). Caspase-3 is a frequently activated death protease; cleaved caspase-3 expression was much less apparent in the cirrhotic livers of wild-type mice compared with those from mice receiving drug treatment (44,45). JAK inhibitor-treated HSCs are positive for active caspase-3, which indicates the presence of a higher apoptotic rate (46). Western blot analysis in this study demonstrated that SHR0302 enhanced the expression of cleaved caspase-3 in HSCs. In agreement with the data regarding the Bcl-2 family of proteins, our study indicated that SHR0302 may induce apoptosis through mechanisms which modulate the Bcl-2 family proteins and caspase-3 activity.

Following the binding of cytokines to their cognate receptor, JAKs phosphorylate STAT to modulate gene expression (47). The JAK/STAT pathway is activated in response to cytokines, growth factors and hormones, mediating a plethora of cellular functions including defense against pathogens, differentiation, proliferation, apoptosis, metabolism and cellular transformation (9). STAT3 plays a key role in many cellular processes such as cell growth and apoptosis, and mediates the expression of a variety of genes in response to stimuli as discussed above; these broad ranging activities make JAK/STAT3 an attractive therapeutic target. Herein, we demonstrated that SHR0302 suppressed the activation of the JAK1/STAT3 signaling pathway, and may be involved in the proliferation, migration, and apoptosis of HSCs as well as HSC collagen production.

Akt signal transduction regulates ECM deposition, HSC activation and is implicated in the development and progression of hepatic fibrosis (15,16). Previous findings have demonstrated that there are complex interactions between the Akt signaling pathway and the JAK signaling pathway. In study of MCF-7 human breast cancer cells and mouse embryonic fibroblasts, it was found that the activity of STAT3 regulates Akt gene expression (48). In hepatic diseases, the JAK-dependent Akt signaling pathway plays a important role in disease progression (49,50). Thus, our results showing that SHR0302 inhibits the Akt signaling pathway is consistent with the findings of other studies of JAK inhibitors suggesting that they potentially inhibit the Akt signaling pathway (51,52).

The effects of JAK inhibitors have been demonstrated in rheumatoid arthritis, colon cancer, lymphoblastic leukemia, myelofibrosis and so on (53–56). For example, ruxolitinib, a JAK1 and JAK2 inhibitor, in clinical trials, alleviated the burdensome manifestations of myelofibrosis, namely splenomegaly and core symptoms (57). The JAK inhibitor AG490 inhibits the leptin-stimulated mRNA expression of JAK1, JAK2 and α1(I) collagen in HSCs (58). Thus, we hypothesized that the JAK inhibitor SHR0302 suppresses hepatic fibrosis, and herein, we proved that the selective JAK inhibitor SHR0302 suppresses certain functions in HSCs.

In conclusion, our hypothesis will require further examination. However, taken together, these findings suggest that the blockade of the JAK/STAT3 signaling pathways significantly decreased cell function and suppressed the Akt signaling pathway in HSCs. JAKs represent an attractive target for the development of novel targeted therapies in various clinical settings including hematologic malignancies, autoimmune disease and organ transplantation. Our study has shown that SHR0302 blocks the downstream STAT3 signaling pathway by abrogating JAK1 activity, and thereby inhibits the activation, proliferation and migration of HSCs as well as collagen synthesis by HSCs. SHR0302 also induces the apoptosis of HSCs. Currently, no optimal antifibrotic drugs available for the clinical treatment of hepatic fibrosis. These results indicate that the JAK inhibitor SHR0302 may have the potential to alleviate hepatic fibrosis.

Acknowledgments

The present study was supported by grants from the National Natural Science Foundation of China (nos. 81300332, 81173075 and 81330081), the Specialized Research Fund for the Doctoral Program of Higher Education in China (no. 20113420120002), the Natural Science Foundation of the Higher Education Institutions of Anhui Province (nos. KJ2012A153 and KJ2014A119) and Anhui Provincial Natural Science Foundation (no. 1308085QH130).

References